SequelSEC

Protalix BioTherapeutics, Inc. PLX

Biological Products, (No Diagnostic Substances) · CIK 0001006281 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$80.62M
Fiscal year ended 2026-06-30
Operating income
$23.29M
Fiscal year ended 2026-06-30
Free cash flow
$7.67M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$113.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.40Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue4.4%10th
Operating margin-10.4%82th
R&D / revenue37.1%21th
Net margin-12.5%76th
FCF margin-25.8%72th
Gross margin48.8%29th
Current ratio2.51x32th
Revenue YoY growth-1.2%42th
CapEx / revenue3.1%43th

Protalix BioTherapeutics, Inc. (PLX) reported revenue of $80.62M and net income of $18.94M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Protalix BioTherapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Protalix BioTherapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$80.62M
Cost of revenue$24.83M
Gross profit$55.79M
Operating income$23.29M
Net income$18.94M
Research & development$19.88M
Weighted-average diluted sharesUnavailable
Pretax income$23.46M
Income tax expense$4.52M
Diluted EPSUnavailable
Selling, general & administrative$12.62M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Protalix BioTherapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$27.42M
Total assets$110.34M
Current assets$92.22M
Total liabilities$38.93M
Current liabilities$31.39M
Total equity incl. NCI$71.40M
Temporary (mezzanine) equityUnavailable
Inventory$32.29M
Accounts receivable$16.50M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Protalix BioTherapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$9.92M
Capital expenditures$2.26M
Investing cash flow-$1.03M
Financing cash flow$296.00K
Net change in cash$9.52M
Stock-based compensation$2.26M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Protalix BioTherapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$7.67M
Gross margin69.2%
Operating margin28.9%
FCF margin9.5%
SBC / revenue2.8%
Current ratio2.94x
Revenue YoY growth30.1%
Net margin23.5%
R&D / revenue24.7%
CapEx / revenue2.8%
Long-term debt / equityUnavailable
Effective tax rate19.3%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PLX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.